SNGXW (Soligenix) Short Interest


SNGXW Soligenix Inc SNGXW
23 GF Score
Price $0.01
! 1 Warning Sign
View Full Analysis

What is Soligenix Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SNGXW vs CYCN, GDTC, TOVX: Short Interest Comparison

For the Biotechnology subindustry, Soligenix's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Short Interest distribution charts can be found below:

* The bar in red indicates where Soligenix's Short Interest falls into.


SNGXW
23GF Score
Soligenix Inc SNGXW
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Soligenix Business Description

Other Exchanges SNGX:USA0A6I:UK
Address 29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
23GF Score

Get the complete analysis for SNGXW

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price